Every Form 4 that Esperion Therapeutics, Inc. (ESPR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ESPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESPR filings page.
Esperion Therapeutics, Inc. director Robert E. Hoffman reported dispositions of common stock and stock options in connection with the closing of a merger in which Esperion became a wholly owned subsidiary of Essence Parent Inc. At the July 13, 2026 effective time, his 85,153 shares of common stock were canceled and converted into the right to receive $3.16 in cash per share plus one contingent value right (CVR) per share. Outstanding restricted stock units vested in full and were similarly converted into cash based on the $3.16 per share cash consideration plus one CVR per underlying share. In-the-money stock options, including 7,040 options at a $0.87 exercise price and 40,000 options at a $1.41 exercise price, were canceled and converted into the right to receive cash equal to the excess of $3.16 over the exercise price per option share, plus one CVR per underlying share. Following these transactions, Hoffman no longer holds these securities.
Esperion Therapeutics director J. Martin Carroll reported the disposition of his equity in connection with the closing of a merger in which Essence MergerCo Inc. merged into Esperion, making Esperion a wholly owned subsidiary of Essence Parent Inc. At the effective time on July 13, 2026, 177,523 shares of common stock held by Carroll, plus 79,873 restricted stock units referenced in the footnotes, were converted into the right to receive $3.16 in cash per share and one contingent value right (CVR) per share. In addition, several in-the-money stock options covering 44,000, 32,500, and 21,000 underlying shares, with exercise prices of $0.87, $2.25, and $1.37 respectively, were canceled and converted into cash equal to the spread over $3.16 per share plus one CVR per underlying share. Following these merger-related cancellations and conversions, Carroll no longer holds these reported securities.
Esperion Therapeutics, Inc. director Jay Shepard reported issuer-directed dispositions tied to the closing of a merger with Essence Parent Inc. and Essence MergerCo Inc. on July 13, 2026. At the effective time, his 164,472 shares of common stock were canceled and converted into the right to receive $3.16 per share in cash plus one contingent value right (CVR) per share. In addition, a total of 97,500 "in-the-money" stock options with exercise prices of $0.87, $2.25 and $1.37 per share were canceled and converted into cash equal to $3.16 minus the exercise price per option share, plus one CVR for each underlying share.
Esperion Therapeutics, Inc. director Seth H. Z. Fischer reported dispositions of equity that occurred at the closing of a merger in which Essence MergerCo Inc. was merged with and into Esperion, making Esperion a wholly owned subsidiary of Essence Parent Inc. At the effective time on July 13, 2026, 141,023 shares of Esperion common stock held directly by Fischer were disposed of in a transaction with the issuer.
Each common share was converted into the right to receive $3.16 in cash per share plus one contingent value right (CVR) providing potential future cash payments upon achievement of specified milestones. All such shares ceased to be outstanding and were automatically canceled. Outstanding equity awards were also converted: 79,873 restricted stock units vested in full and were canceled for the same per-share cash amount plus one CVR per underlying share, subject to tax withholding.
In addition, three in-the-money stock option grants covering 44,000; 32,500; and 21,000 shares, with exercise prices of $0.87, $2.25, and $1.37 per share, respectively, were canceled and converted into cash equal to the excess of the $3.16 per-share cash consideration over the applicable exercise price, plus one CVR per underlying share. Following these issuer dispositions, Fischer reported no remaining direct holdings of Esperion common stock or the reported options.
Esperion Therapeutics, Inc. director John Craig Thompson reported the disposition of his equity in connection with the closing of a merger in which Essence MergerCo Inc. merged with Esperion, making Esperion a wholly owned subsidiary of Essence Parent Inc.
At the effective time on July 13, 2026, each share of Esperion common stock was converted into the right to receive $3.16 in cash per share plus one contractual contingent value right (CVR) per share, representing rights to potential future cash payments upon achievement of specified milestones. All common shares then ceased to be outstanding and were automatically canceled.
Thompson’s holdings included 79,873 restricted stock units, each converted into the cash amount equal to the per share cash consideration plus one CVR per underlying share, and 40,000 stock options with a per share exercise price of $1.00, treated as in-the-money options and canceled in exchange for cash equal to the spread over $3.16 plus one CVR per underlying share. Following these issuer dispositions, his reported direct holdings of the affected securities were reduced to zero.
Esperion Therapeutics, Inc. Chief Commercial Officer John B. Harlow Jr. reported a disposition of equity awards tied to the company’s merger with Essence Parent Inc. At the July 13, 2026 Effective Time, all common shares were converted into the right to receive $3.16 per share in cash plus one contingent value right (CVR). Harlow’s 424,536 restricted stock units vested in full and were canceled in exchange for the same cash-and-CVR merger consideration per underlying share, leaving him with no remaining directly held common shares.
Esperion Therapeutics, Inc. executive Benjamin Looker, Chief Legal Officer, reported dispositions of equity in connection with the closing of a merger in which Esperion became a wholly owned subsidiary of Essence Parent Inc. At the July 13, 2026 effective time, each share of common stock was converted into the right to receive $3.16 in cash per share plus one contingent value right (CVR), after which all common shares were canceled. Looker disposed of 667,524 shares of common stock and stock options covering 620,230 shares, which were canceled and converted into cash payments based on the excess of the $3.16 per share cash consideration over their respective exercise prices, plus CVRs, consistent with the merger terms.
Esperion Therapeutics CFO Benjamin Halladay reported the disposition of his equity in connection with Esperion’s merger with Essence Parent Inc. On July 13, 2026, all of his 705,410 shares of common stock were transferred to the issuer as part of the merger consideration, and he no longer holds these shares. In addition, stock options for 221,270 shares at $2.44, 213,000 shares at $1.50, and 200,000 shares at $2.05 per share were canceled and disposed of to the issuer. Under the merger terms, each share of common stock and each in-the-money option was converted into the right to receive $3.16 in cash per share plus one contingent value right, providing potential future cash payments if specified milestones are achieved.
Esperion Therapeutics, Inc. completed a merger in which President and CEO Sheldon L. Koenig disposed of his equity positions to the issuer at the merger effective time. The filing reports the disposition of 2,121,094 shares of common stock and several stock option grants covering 647,460, 753,000, and 642,000 underlying shares. Each common share was converted into the right to receive $3.16 in cash per share plus one contingent value right (CVR). Each in-the-money stock option was canceled and converted into cash equal to the excess of the $3.16 per share cash consideration over its exercise price, plus one CVR for each underlying share.
Esperion Therapeutics, Inc. Chief Legal Officer Benjamin Looker reported an open-market sale of 11,824 shares of common stock. The shares were sold at an average price of $3.155 per share to satisfy tax obligations on recently vested restricted stock units. After this transaction, he continues to hold 667,524 shares directly.
Esperion Therapeutics, Inc. President and CEO Sheldon L. Koenig reported an open-market sale of 53,588 shares of common stock at an average price of $3.155 per share. According to the footnote, the shares were sold to satisfy tax obligations on vested restricted stock units.
After this transaction, Koenig directly holds 2,119,111 shares of Esperion common stock, indicating he retains a substantial equity stake in the company despite the sale for tax purposes.
Esperion Therapeutics, Inc. Chief Financial Officer Benjamin Halladay reported an open-market sale of 10,773 shares of common stock at $3.155 per share. According to the filing, the shares were sold to satisfy tax obligations arising from vested restricted stock units. After this transaction, Halladay directly holds 702,829 shares, indicating he retains a substantial equity position in the company.
THOMPSON JOHN CRAIG reported acquisition or exercise transactions in this Form 4 filing.
Esperion Therapeutics director John Craig Thompson received an equity award of 79,873 shares of common stock as compensation. The award was granted at no cash cost per share and represents his entire reported direct holding after the transaction. These shares vest in full on the earlier of May 28, 2027 or the company’s next annual meeting of stockholders following May 28, 2026.
Esperion Therapeutics director Jay Shepard reported an equity award of 79,873 shares of Common Stock. The shares were granted at no purchase price as a stock award and increase his direct holdings to 164,472 shares after the transaction.
The award vests in full on the earlier of May 28, 2027, or the company’s next annual meeting of stockholders following May 28, 2026, aligning vesting with future board service. This filing reflects compensation-related share acquisition rather than an open-market purchase or sale.
Hoffman Robert E. reported acquisition or exercise transactions in this Form 4 filing.
Esperion Therapeutics director Robert E. Hoffman received an equity grant of 79,873 shares of Common Stock, reported at a price of $0.00 per share as a compensation award. Following this grant, he directly holds 85,153 shares of Esperion common stock.
The award vests in full on the earlier of May 28, 2027 or Esperion’s next annual meeting of stockholders following May 28, 2026, linking vesting to either time-based service or the company’s stockholder meeting schedule.
Fischer Seth H. Z. reported acquisition or exercise transactions in this Form 4 filing.
Esperion Therapeutics director Seth H. Z. Fischer received an equity award of 79,873 shares of common stock as compensation. The grant carried a price of $0.00 per share and increased his directly held stake to 141,023 shares.
The award vests in full on the earlier of May 28, 2027, or the company’s next annual meeting of stockholders following May 28, 2026, meaning the shares are subject to a service-based vesting condition rather than being immediately unrestricted.
CARROLL J MARTIN reported acquisition or exercise transactions in this Form 4 filing.
Esperion Therapeutics, Inc. director J. Martin Carroll received an equity grant of 79,873 shares of Common Stock as compensation. The shares were awarded at no cash cost per share and increase his direct holdings to 177,523 shares. The award vests in full on the earlier of May 28, 2027 or the company’s next annual meeting of stockholders following May 28, 2026.
Esperion Therapeutics, Inc. Chief Legal Officer Benjamin Looker reported an open-market sale of 5,708 shares of common stock. The shares were sold at an average price of $2.703 per share to satisfy tax obligations on vested restricted stock units. After this transaction, he directly holds 679,348 shares, indicating that the sale represents a small portion of his overall position.
Esperion Therapeutics’ President and CEO Sheldon L. Koenig reported an open-market sale of 25,578 shares of common stock at $2.719 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from vested restricted stock units.
After this transaction, Koenig directly holds 2,172,699 shares of Esperion Therapeutics common stock. This filing reflects a tax-related disposition rather than a discretionary reduction of his overall shareholding.
Esperion Therapeutics Chief Financial Officer Benjamin Halladay reported an open-market sale of 6,424 shares of common stock at $2.705 per share. According to the footnote, the shares were sold to satisfy tax obligations on vested restricted stock units. After this tax-related sale, he directly holds 713,602 shares.
Esperion Therapeutics Chief Legal Officer Benjamin Looker reported receiving new equity compensation. He was granted a stock option for 269,230 shares of Common Stock at an exercise price of $2.44 per share, expiring on March 13, 2036.
He also received 300,840 shares of Common Stock as a direct grant, bringing his direct Common Stock holdings to 685,056 shares after the award. The stock option award will vest over four years in equal quarterly installments, starting on June 15, 2026.
Esperion Therapeutics, Inc. reported that President and CEO Sheldon L. Koenig received new equity awards. He was granted a stock option covering 647,460 shares of common stock at an exercise price of $2.44 per share, expiring on March 13, 2036, along with 723,760 shares of common stock as a separate award, both at no cash cost to him.
The filing notes that this award will vest over a four-year period in equal quarterly installments beginning on June 15, 2026 Following these grants, Koenig directly holds 2,198,277 shares of Esperion common stock, which includes 3,930 shares recently acquired through Esperion's Employee Stock Purchase Plan.
Esperion Therapeutics Chief Financial Officer Benjamin Halladay reported equity awards. He received a grant of 221,270 stock options to buy Common Stock at an exercise price of $2.44 per share, expiring on March 13, 2036. He was also granted 247,430 shares of Common Stock, bringing his direct holdings to 720,026 shares. The option award will vest over four years in equal quarterly installments, starting on June 15, 2026. Halladay’s reported holdings include 5,071 shares recently acquired through Esperion’s Employee Stock Purchase Plan.
Esperion Therapeutics General Counsel Benjamin Looker reported a small sale of company stock. On 01/20/2026, he sold 1,689 shares of Esperion Therapeutics common stock at a price of $2.882 per share. According to the filing, the shares were sold to satisfy tax obligations arising from vested restricted stock units, meaning the transaction was linked to covering taxes rather than a discretionary open-market sale. Following this transaction, he beneficially owned 384,216 shares directly.
Esperion Therapeutics, Inc. reported an insider stock transaction by its President and CEO, who is also a director. On 12/17/2025, the insider sold 48,244 shares of common stock at $3.673 per share. After this transaction, the insider beneficially owned 1,470,587 shares of Esperion common stock.
The company states that these shares were sold to satisfy tax obligations arising from vested restricted stock units, meaning the sale was tied to covering taxes rather than a discretionary reduction of ownership.
Esperion Therapeutics Chief Financial Officer Sheldon L. Koenig reported a routine stock transaction involving company shares. On 12/17/2025, he sold 7,337 shares of Esperion Therapeutics common stock at a price of $3.667 per share. According to the filing, these shares were sold to cover tax obligations arising from the vesting of restricted stock units. After this sale, Koenig beneficially owned 467,525 shares of Esperion common stock, held directly.
Esperion Therapeutics, Inc. reported an insider stock transaction by its General Counsel. On 12/17/2025, the officer sold 6,517 shares of common stock at a price of $3.667 per share. According to the explanation, these shares were sold to satisfy tax obligations arising from vested restricted stock units, meaning the sale was related to tax withholding rather than a discretionary liquidation of holdings. Following this transaction, the reporting person directly owned 385,905 shares of Esperion common stock.